RecruitingPhase 2NCT06528847

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

Benmelstobart (TQB2450) for Adjuvant Therapy in Pathologic Stage IB, IASLC Grade 3 Invasive Lung Adenocarcinomas: A Prospective, Single-arm, Phase 2 Clinical Trial

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Enrollment

62 participants

Start Date

Jun 5, 2024

Study Type

INTERVENTIONAL

Summary

This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma without EGFR active mutations or ALK rearrangement.

Eligibility

Min Age: 18 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether adding an immunotherapy drug called benmelstobart after surgery can reduce the chance of early-stage lung adenocarcinoma (a type of lung cancer) coming back. It focuses on a specific subtype: stage IB, grade 3, which has a higher risk of recurrence. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with stage IB, grade 3 invasive lung adenocarcinoma (confirmed by pathology) - You have had surgical removal of the tumor - You are in generally good health **You may NOT be eligible if...** - Your lung cancer is a different stage or type - You have not had surgery, or surgery did not fully remove the cancer - You have serious other medical conditions - You are unable to tolerate immunotherapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBenmelstobart

The PD-L1 inhibitor Benmelstobart (TQB2450) is administered as an adjuvant therapy in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma who do not have EGFR active mutations or ALK rearrangement.

Locations(1)

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06528847